Alkermes plc

Alkermes plc Earnings Recaps

ALKS Health Care 3 recaps
Q1 2026 May 8, 2026

Alkermes shares rose 3.4% post-earnings, reflecting investor approval of robust proprietary product sales growth and early contributions from the recently acquired sleep medicine asset, LUMRYZ.

Key takeaways
  • Proprietary product net sales grew 38% year-over-year to $338.1 million, driven by strong demand across psychiatry and addiction franchises.
  • VIVITROL sales reached $112.4 million, supported by favorable localized market dynamics; 2026 guidance reaffirmed at $460–480 million.
  • Psychiatry portfolio net sales included ARISTADA at $93.8 million and LYBALVI at $92.4 million, with LYBALVI TRX growing 21% year-over-year; full-year sales guidance maintained.
  • Favorable gross-to-net adjustments contributed approximately $14 million of upside in Q1, primarily from improved patient mix.
  • Integration of Avadel and the LUMRYZ launch added six weeks of commercial contribution and established Alkermes’ presence in the sleep medicine market ahead of future pipeline opportunities.
Full recap
Q3 2025 Oct 28, 2025

Alkermes reported robust third-quarter results, driven by strong product performance and strategic advancements, prompting an increase in 2025 financial guidance.

Key takeaways
  • Total revenues reached $394.2 million, with proprietary product sales increasing 16% year-over-year to $317.4 million.
  • The proposed acquisition of Avadel Pharmaceuticals is expected to enhance Alkermes' position in the sleep medicine market and diversify its product portfolio.
  • GAAP net income for the quarter was $82.8 million, demonstrating strong profitability alongside a significant gross-to-net benefit from Medicaid utilization.
  • Research and development expenses rose to $81.7 million, reflecting investment in ongoing and upcoming clinical studies for orexin receptor agonists.
  • Full-year 2025 guidance increased, underlining confidence in sustained commercial traction and operational execution.
Full recap
Q2 2025 Aug 2, 2025

Alkermes delivered strong financial results in Q2 2025, achieving robust revenue growth and successfully advancing its innovative treatment for narcolepsy, positioning the company for significant future growth.

Key takeaways
  • Q2 total revenues reached $390.7 million, with proprietary product sales growing 14% year-over-year to $307.2 million.
  • Alixorexton's Phase II study, Vibrance 1, showed significant effects on wakefulness and cognitive improvements in narcolepsy patients, setting the stage for Phase III trials.
  • The company boasts a solid financial position with $1 billion in cash, no debt, and expected Q3 net sales between $280 million to $300 million.
Full recap